Provided by Tiger Fintech (Singapore) Pte. Ltd.

Artelo Biosciences, Inc.

1.04
+0.05105.16%
Post-market: 0.9900-0.0500-4.81%18:28 EDT
Volume:21.61K
Turnover:21.78K
Market Cap:3.36M
PE:-0.34
High:1.04
Open:0.9700
Low:0.9555
Close:0.9890
Loading ...

Company Profile

Company Name:
Artelo Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
6
Office Location:
505 Lomas Santa Fe,Suite 160,Solana Beach,California,United States
Zip Code:
92075
Fax:
- -
Introduction:
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Directors

Name
Position
Gregory D. Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director
Connie Matsui
Director, Chairperson of the Board
Douglas Blayney
Director
Gregory Reyes
Director
R. Martin Emanuele
Director
Steven Kelly
Director
Tamara A. Seymour
Director

Shareholders

Name
Position
Gregory D. Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director